Cargando…
Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis
BACKGROUND: Stereotactic body radiotherapy (SBRT) is increasingly used to treat oligometastatic disease (OMD), but the effect of metastasis timing on patient outcomes remains uncertain. METHODS: An international database of patients with OMD treated with SBRT was assembled with rigorous quality assu...
Autores principales: | Chen, Xuguang, Chen, Hanbo, Poon, Ian, Erler, Darby, Badellino, Serena, Biswas, Tithi, Dagan, Roi, Foote, Matthew, Louie, Alexander V., Ricardi, Umberto, Sahgal, Arjun, Redmond, Kristin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446561/ https://www.ncbi.nlm.nih.gov/pubmed/34432390 http://dx.doi.org/10.1002/cam4.4133 |
Ejemplares similares
-
Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis
por: Poon, Ian, et al.
Publicado: (2020) -
Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease
por: Cao, Yilin, et al.
Publicado: (2021) -
Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study
por: Baydoun, A., et al.
Publicado: (2021) -
Stereotactic Radiotherapy for Oligometastasis
por: Otake, Sotaro, et al.
Publicado: (2019) -
Stereotactic radiotherapy for early stage non-small cell lung cancer
por: Ricardi, Umberto, et al.
Publicado: (2015)